none - observational study: none - observational study
Study summary
Dementia, in its various forms, is characterized by a generalized cognitive decline that can significantly compromise personal autonomy and quality of life. Mild Cognitive Impairment (MCI), although not classified as an overt form of dementia, represents a condition at evolutionary risk and is considered a crucial transitional stage for the early detection of cognitive decline. Understanding the impact of dementia and MCI from a multidimensional perspective is now essential to fully grasp the repercussions of these conditions on patients' daily lives. The present protocol aims to investigate key aspects related to these disorders, with the objective of exploring cognitive functioning, the degree of impairment in activities of daily living, and the presence of neuropsychiatric symptoms. Through an integrated and multidisciplinary approach, the study seeks to enhance clinical management and patient care, promoting more effective, targeted, and personalized interventions.
Eligibility
Sex
ALL
Min age
50 Years
Max age
86 Years
Healthy volunteers
No
Inclusion Criteria:
* Age between 50 and 86 years.
* Suspected or confirmed diagnosis of dementia or mild cognitive impairment (MCI).
* Referral to the neuropsychology clinic for initial assessment or clinical monitoring.
* Absence of behavioral, psychiatric, or sensory disorders severe enough to significantly impair cognitive testing or completion of questionnaires.
Exclusion Criteria:
* Presence of neurological disorders other than dementia or MCI (e.g., recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, atypical neurodegenerative diseases).
* Unstable major psychiatric comorbidities at the time of assessment (e.g., schizophrenia, bipolar disorder in active phase, untreated severe depression).
* Uncorrected severe sensory deficits (visual or auditory) affecting the validity of cognitive or functional assessments.
* Use of medications with significant cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of evaluation.
* Presence of terminal medical or oncological conditions or other illnesses significantly interfering with the assessment procedures.
Primary outcome measure(s)
Dementia or Mild Cognitive Impairment (MCI) with ADL — 12 MONTHS The primary outcome variable considered for calculation is the score of the Activities of Daily Living (ADL) scale, used as the main index of functional autonomy in subjects with dementia or mild cognitive impairment (MCI).
Trial sites (1)
Facility
City
Region
Status
Irccs Centro Neurolesi Bonino Pulejo
Messina
ME
Recruiting
More IRCCS Centro Neurolesi Bonino Pulejo trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
